The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated ...

This is one huge reason to believe in the future of Novo Nordisk (NYSE: NVO), the Danish company behind the immensely popular Wegovy obesity treatment. Last week the company earned a new feather in ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

Pharmaceutical companies behind weight loss and diabetes medication such as Ozempic are facing a lawsuit that could ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

New pill orforglipron was associated with a significant reduction in body weight and better cholesterol, triglycerides and blood pressure.

It faces more than 1,800 lawsuits consolidated in federal court in Pennsylvania and new claims emerging weekly, according to ...

In April 2025 , Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND ...